Dr. Daniel Sullivan obtained his undergraduate degree in Chemical and Biological Engineering at the University of Alabama in 2009. He attended medical school at the University of Alabama, where he graduated in 2014, and studied a retinoid modulator of leukotriene A4 hydrolase activity with the goal of inhibiting neutrophilic inflammation in COPD during a Howard Hughes Medical Institute Medical Research Fellowship. He moved to Dallas to complete his Internal Medicine residency at the University of Texas Southwestern Medical Center where he examined the role of donor specific antibodies in lung transplant recipients and their contribution to bronchiolitis obliterans and survival. He enjoys ultimate frisbee, bouldering, cooking and gardening and has specific interests in immunology and inflammation.
Dr. Sullivan’s current research revolves around identifying the causal signals and cell types that initiate the fibrotic response in idiopathic pulmonary fibrosis (IPF). He and his mentor, Dr. Jonathan Alder, PhD, are focused on the secretory changes that occur when telomere-mediated injury results in cellular senescence of the alveolar epithelium. They theorize that changes in the secretome of the alveolar epithelium are likely the initial profibrotic cue in IPF. Dr. Sullivan is currently exploring this theory on the cell biology, biochemical, synthetic genetics, and computational genetics fronts. His goal is to identify novel causal secreted factors that will ultimately lead toward the development of targeted therapies for this intractable disease.
2004 – 2009 : The University of Alabama, B.S.E. Chemical and Biological Engineering
2009 – 2012 : University of Alabama School of Medicine
2012 – 2013 : Howard Hughes Medical Institute Medical Research Fellowship
2013 – 2014 : University of Alabama School of Medicine, M.D..
2014 – 2017 : The University of Texas Southwestern Medical Center/Internal Medicine, Internal Medicine Residency
2017 – present : University of Pittsburgh, Pulmonary, Allergy & Critical Care Medicine Fellow